ADC Therapeutics S.A.
ADCTNYSEHealthcare● Active
$1.02
+$0.04(+3.82%)
Market Cap$129098865
P/E Ratio—
52W High$4.98
52W Low$0.7796
ADC Therapeutics S.A. (ADCT) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADCT · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($142.62M) | ($157.85M) | ($240.05M) | ($157.13M) | ($230.03M) |
| Depreciation & Amort. | $1.88M | $3.28M | $3.27M | $5.74M | $2.63M |
| Stock-Based Comp. | $6.91M | $6.57M | $13.49M | $50.64M | $60.48M |
| Change in Working Capital | ($25.36M) | $3.83M | $44.27M | ($49.03M) | ($15.71M) |
| Net Cash from Operations | ($141.17M) | ($123.83M) | ($118.69M) | ($138.31M) | ($233.38M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.26M) | ($0.87M) | ($3.22M) | ($0.69M) | ($6.38M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $0.40M | ($0.87M) | ($3.22M) | ($0.69M) | ($6.67M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | ($1.31M) | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | ($2.71M) | $48.61M |
| Net Cash from Financing | $150.94M | $97.05M | $73.88M | ($0.90M) | $267.39M |
| Free Cash Flow | |||||
| Free Cash Flow | ($141.44M) | ($124.70M) | ($121.90M) | ($139.00M) | ($239.75M) |
| FCF Margin %(computed) | -173.85% | -176.04% | -175.25% | -66.22% | -706.88% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more ADC Therapeutics S.A. data
About ADC Therapeutics S.A. (ADCT) Cash Flow Statement
ADC Therapeutics S.A. generated operating cash flow of ($0.14B) and free cash flow of ($0.14B) for 2025 — a FCF margin of -173.85%. Capital expenditure was ($0.00B).
Frequently asked questions
ADCT · 4 questionsADC Therapeutics S.A. generated free cash flow of ($0.14B) for 2025, down 13.4% year-over-year.
ADCT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10